Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928605 | 0.88 | EPHX2 (0.67) | EPHX2ALDH1A1TP53MEN1KMT2A | |
| SCHEMBL13602125 | 0.86 | EPHX2 (0.58) | EPHX2ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL3922371 | 0.85 | EPHX2 (0.69) | EPHX2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3917480 | 0.85 | EPHX2 (0.69) | EPHX2NPC1RAB9AGAAMEN1 | |
| SCHEMBL3920876 | 0.84 | POLB (0.71) | ALDH1A1NPC1MEN1KMT2AL3MBTL1 | |
| SCHEMBL13602124 | 0.84 | EPHX2 (0.55) | EPHX2ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL3918782 | 0.84 | HSD11B1 (0.54) | EPHX2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL14342597 | 0.83 | EPHX2 (0.61) | EPHX2ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL3927982 | 0.82 | EPHX2 (0.71) | EPHX2ALDH1A1TP53MEN1KMT2A | |
| SCHEMBL3918370 | 0.81 | EPHX2 (0.69) | EPHX2ALDH1A1NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | claimed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | EPHX2 2010/4885ALDH1A1 46/4885NPC1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.